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Based on the International Diabetes Federation (IDF)
estimates, there were 136.700 people with diabetes mel-
litus in Republic of Macedonia in 2012, and this number
is projected to increase to 166.000 in 2030. National
Guidelines on the treatment and control of type 2 dia-
betes have already been published in the Official Journal.
Most modern diabetes treatments are available; reim-
bursement covering test-strips metformin, sulphonylureas,
meglitinides, human and analogue insulins, and certain
number of insulin pumps. Insulins, analogue and human,
are fully reimbursed, with no co-payment by the patients,
and are fully covered by the State Budget for all patients,
no matter if insured or not. More than half of the all
treated diabetes patents are insulin treated, with 83% and
92% penetration of insulin analogues in volume and
value, respectively, considerably higher relative to many
more developed EU/EEA countries.
Macedonia appears to be among the European and
world leaders if cost of insulin analogues as fraction of
Gross Domestic Product per capita is taken into consid-
eration, resulting in a challenge for the sustainability of
the system since a major part of the diabetes care bud-
get is allocated for insulin analogues. The system is
facing a need to rationalize the insulin treatment costs
given the expected steep rise in the diabetes prevalence,
and the need of comprehensive diabetes care including
emerging treatments.
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